Debra Durso-Bumpus Sells 333 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Debra Durso-Bumpus sold 333 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $111.15, for a total transaction of $37,012.95. Following the sale, the insider now directly owns 43,763 shares of the company’s stock, valued at $4,864,257.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Debra Durso-Bumpus also recently made the following trade(s):

• On Friday, June 21st, Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock. The stock was sold at an average price of $104.19, for a total transaction of $7,713,602.46.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $109.03 on Thursday. The stock has a market capitalization of $6.83 billion, a P/E ratio of -22.67 and a beta of 0.63. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $104.34 and its 200 day moving average is $93.19. Blueprint Medicines Co. has a 12 month low of $43.89 and a 12 month high of $111.89.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.32. The company had revenue of $96.12 million for the quarter, compared to analysts’ expectations of $82.58 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. On average, sell-side analysts anticipate that Blueprint Medicines Co. will post -5.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BPMC. SVB Leerink upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and boosted their price target for the stock from $50.00 to $97.00 in a report on Monday, May 6th. Wedbush restated an “outperform” rating and set a $110.00 price target on shares of Blueprint Medicines in a report on Friday, April 26th. Citigroup boosted their price target on shares of Blueprint Medicines from $65.00 to $76.00 and gave the stock a “sell” rating in a report on Friday, May 3rd. Stephens began coverage on shares of Blueprint Medicines in a report on Tuesday, May 14th. They set an “overweight” rating and a $140.00 price target on the stock. Finally, The Goldman Sachs Group boosted their price target on shares of Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a report on Monday, May 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $110.20.

Hedge Funds Weigh In On Blueprint Medicines

A number of institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Blueprint Medicines by 0.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock worth $3,451,000 after buying an additional 145 shares during the last quarter. US Bancorp DE increased its holdings in shares of Blueprint Medicines by 5.2% in the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock worth $353,000 after buying an additional 183 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after buying an additional 193 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Blueprint Medicines by 1.7% in the 4th quarter. Principal Financial Group Inc. now owns 14,510 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 247 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of Blueprint Medicines by 3.9% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 6,834 shares of the biotechnology company’s stock worth $648,000 after buying an additional 256 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.